Kalaris Therapeutics, Inc.
KLRS
$3.08
$0.5220.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | 06/30/2024 | |||
|---|---|---|---|---|---|
| Net Income | -11.35M | -10.20M | -5.65M | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | 0.00 | 186.00K | 1.34M | ||
| Total Other Non-Cash Items | 591.00K | 223.00K | 510.00K | ||
| Change in Net Operating Assets | -1.78M | 2.35M | -172.00K | ||
| Cash from Operations | -12.54M | -7.44M | -3.97M | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -- | ||
| Total Debt Issued | 0.00 | 7.50M | 5.00M | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | 0.00 | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | 0.00 | 99.77M | -17.00K | ||
| Cash from Financing | 0.00 | 107.27M | 4.98M | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -12.54M | 99.83M | 1.01M | ||